CLAIMS

What is claimed is:

1. ~~A composition for the treatment or prevention of a viral respiratory infection in a subject, the composition comprising a nutritionally or pharmaceutically effective amount of nobiletin or a salt, solvate, or prodrug thereof.~~
2. ~~The composition according to claim 1, wherein the subject has and/or is diagnosed with a pneumonia caused by a viral respiratory infection.~~
3. ~~The composition according to claim 1 or claim 2, wherein the viral respiratory infection is selected from the group consisting of the common cold, influenza A, influenza B, a coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and any combination thereof.~~
4. ~~The composition according to claim 3, wherein the viral respiratory infection is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~~
5. ~~The composition according to claim 1, further comprising one or more additional polymethoxylated flavones (PMFs).~~
6. ~~The composition according to claim 5, wherein the one or more additional polymethoxylated flavones (PMFs) is selected from the group consisting of tangeretin, sinensetin, and any combination thereof.~~
7. ~~The composition according to claim 1, further comprising one or more omega-3 fatty acids.~~
8. ~~The composition according to claim 7, wherein the one or more omega-3 fatty acids comprises alpha-linolenic acid.~~
9. ~~The composition according to claim 7, wherein the one or more omega-3 fatty acids comprises at least one very long chain omega-3 fatty acid selected from the group consisting~~

of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), docosahexaenoic acid (DHA), and any combination thereof.

10. The composition according to claim 7, wherein the one or more omega-3 fatty acids comprises alpha-linolenic acid and at least one selected from the group consisting of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA).

11. The composition according to claim 1, further comprising at least one compound selected from the group consisting of natural triglycerides, restructured triglycerides, phospholipids, ethyl esters, free fatty acids, and any combination thereof.

12. The composition according to claim 1, comprising from about 0.25% to about 60% by weight nobiletin as compared to the total weight of the composition.

13. A method for the treatment or prevention of a viral respiratory infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition, the composition comprising nobiletin or a salt, solvate, or prodrug thereof.

14. The method according to claim 13, wherein the subject has and/or is diagnosed with a pneumonia caused by a viral respiratory infection.

15. The method according to claim 13 or claim 14, wherein the viral respiratory infection is selected from the group consisting of the common cold, influenza A, influenza B, a coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and any combination thereof.

16. The method according to claim 13 or claim 14, wherein the viral respiratory infection is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17. The method according to claim 13, wherein the composition further comprises one or more additional polymethoxylated flavones (PMFs).

18. The method according to claim 17, wherein the one or more additional polymethoxylated flavones (PMFs) is selected from the group consisting of tangeretin, sinensetin, and any combination thereof.

19. The method according to claim 13, wherein the composition further comprises one or more omega-3 fatty acids.

20. The method according to claim 19, wherein the one or more omega-3 fatty acids comprises alpha-linolenic acid.

21. The method according to claim 19, wherein the one or more omega-3 fatty acids comprises at least one very long chain omega-3 fatty acid selected from the group consisting of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), docosahexaenoic acid (DHA), and any combination thereof.

22. The method according to claim 19, wherein the one or more omega-3 fatty acids comprises alpha-linolenic acid and at least one selected from the group consisting of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA).

23. The method according to claim 13, wherein the composition further comprises at least one compound selected from the group consisting of natural triglycerides, restructured triglycerides, phospholipids, ethyl esters, free fatty acids, and any combination thereof.

24. The method according to claim 13, wherein the composition comprises from about 0.25% to about 60% by weight nobiletin as compared to the total weight of the composition.

25. The method according to claim 13, wherein the subject is a mammal.

26. The method according to claim 13, wherein the subject is a human.

1. A composition for the treatment or prevention of a viral respiratory infection in a subject, the composition comprising a nutritionally or pharmaceutically effective amount of nobiletin or a salt, solvate, or prodrug thereof.
2. The composition according to claim 1, wherein the subject has and/or is diagnosed with a pneumonia caused by a viral respiratory infection.
3. The composition according to claim 1 or claim 2, wherein the viral respiratory infection is selected from the group consisting of the common cold, influenza A, influenza B, a coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and any combination thereof.
4. The composition according to claim 1, further comprising one or more additional polymethoxylated flavones (PMFs) selected from the group consisting of tangeretin, sinensetin, and any combination thereof.
5. The composition according to claim 1, further comprising one or more omega-3 fatty acids.
6. The composition according to claim 5, wherein the one or more omega-3 fatty acids comprises alpha-linolenic acid.
7. The composition according to claim 5, wherein the one or more omega-3 fatty acids comprises at least one very long chain omega-3 fatty acid selected from the group consisting of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), docosahexaenoic acid (DHA), and any combination thereof.
8. The composition according to claim 5, wherein the one or more omega-3 fatty acids comprises alpha-linolenic acid and at least one selected from the group consisting of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA).

9. The composition according to claim 1, further comprising at least one compound selected from the group consisting of natural triglycerides, restructured triglycerides, phospholipids, ethyl esters, free fatty acids, and any combination thereof.

10. The composition according to claim 1, comprising from about 0.25% to about 60% by weight nobiletin as compared to the total weight of the composition.

11. A method for the treatment or prevention of a viral respiratory infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition, the composition comprising nobiletin or a salt, solvate, or prodrug thereof.

12. The method according to claim 11, wherein the subject has and/or is diagnosed with a pneumonia caused by a viral respiratory infection.

13. The method according to claim 11 or claim 12, wherein the viral respiratory infection is selected from the group consisting of the common cold, influenza A, influenza B, a coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and any combination thereof.

14. The method according to claim 13, wherein the composition further comprises one or more additional polymethoxylated flavones (PMFs) selected from the group consisting of tangeretin, sinensetin, and any combination thereof.

15. The method according to claim 13, wherein the composition further comprises one or more omega-3 fatty acids.

16. The method according to claim 15, wherein the one or more omega-3 fatty acids comprises alpha-linolenic acid.

17. The method according to claim 15, wherein the one or more omega-3 fatty acids comprises at least one very long chain omega-3 fatty acid selected from the group consisting of

eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), docosahexaenoic acid (DHA), and any combination thereof.

18. The method according to claim 15, wherein the one or more omega-3 fatty acids comprises alpha-linolenic acid and at least one selected from the group consisting of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA).

19. The method according to claim 15, wherein the composition further comprises at least one compound selected from the group consisting of natural triglycerides, restructured triglycerides, phospholipids, ethyl esters, free fatty acids, and any combination thereof.

20. The method according to claim 11, wherein the composition comprises from about 0.25% to about 60% by weight nobiletin as compared to the total weight of the composition.